SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern DOI Creative Commons
Natália Satchiko Hojo-Souza, Julia Castro, Graziella Gomes Rivelli

et al.

Vaccine, Journal Year: 2024, Volume and Issue: 42(26), P. 126394 - 126394

Published: Oct. 4, 2024

Language: Английский

An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants DOI Creative Commons
Fábio Mambelli, Ana Carolina V. S. C. de Araujo, Jéssica Pires Farias

et al.

Pathogens, Journal Year: 2025, Volume and Issue: 14(1), P. 23 - 23

Published: Jan. 1, 2025

The COVID-19 pandemic has posed a significant threat to global health systems, with extensive impacts across many sectors of society. been responsible for millions deaths worldwide since its first identification in late 2019. Several actions have taken prevent the disease, including unprecedented fast development and vaccination campaigns, which were pivotal reducing symptoms deaths. Given impact pandemic, continuous changes virus, present vaccine technologies, this review analyzes how, so far, we met challenge by emergence new variants discusses how next-generation pan-coronavirus vaccines, enhanced longevity breadth immune responses, may be tackled alternative administration routes antigen delivery platforms. By addressing these critical aspects, aims contribute ongoing efforts achieve long-term control COVID-19, stimulating discussion work on vaccines capable facing future waves infection.

Language: Английский

Citations

2
The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development DOI Creative Commons
Haiyun Yu, Fei Guan,

Heather Miller

et al.

Emerging Microbes & Infections, Journal Year: 2022, Volume and Issue: 12(1)

Published: Dec. 30, 2022

ABSTRACTThe coronavirus disease 2019 (COVID-19) has caused enormous health risks and global economic disruption. This is by the severe acute respiratory syndrome 2 (SARS-CoV-2). The SARS-CoV-2 nucleocapsid protein a structural involved in viral replication assembly. There accumulating evidence indicating that multi-functional, playing key role pathogenesis of COVID-19 antiviral immunity against SARS-CoV-2. Here, we summarize its potential application prevention COVID-19, which based on inflammation, cell death, innate immunity, adaptive immunity.

Language: Английский

Citations

29
The role of SARS-CoV-2 N protein in diagnosis and vaccination in the context of emerging variants: present status and prospects DOI Creative Commons

Wanchen Song,

Zhongbiao Fang, Feike Ma

et al.

Frontiers in Microbiology, Journal Year: 2023, Volume and Issue: 14

Published: Aug. 14, 2023

Despite many countries rapidly revising their strategies to prevent contagions, the number of people infected with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues surge. The emergent variants that can evade immune response significantly affect effectiveness mainstream vaccines and diagnostic products based on original spike protein. Therefore, it is essential focus highly conserved nature nucleocapsid protein as a potential target in field diagnostics. In this regard, our review initially discusses structure, function, mechanism action N Based discussion, we summarize relevant research in-depth development application methods protein, such serology nucleic acid detection. Such valuable information aid designing more efficient vaccine tools could help end SARS-CoV-2 pandemic.

Language: Английский

Citations

18
Molecular characterization of SARS-CoV-2 nucleocapsid protein DOI Creative Commons
Yanping Huang,

Junkai Chen,

Siwei Chen

et al.

Frontiers in Cellular and Infection Microbiology, Journal Year: 2024, Volume and Issue: 14

Published: May 23, 2024

Corona Virus Disease 2019 (COVID-19) is a highly prevalent and potent infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Until now, the world still endeavoring to develop new ways diagnose treat COVID-19. At present, clinical prevention treatment of COVID-19 mainly targets spike protein on surface SRAS-CoV-2. However, with continuous emergence SARS-CoV-2 Variants concern (VOC), targeting therapy shows high degree limitation. The Nucleocapsid Protein (N protein) conserved in virus evolution involved key process viral infection assembly. It most expressed structural after humans has immunogenicity. Therefore, N as factor replication basic research application great potential value. This article reviews progress structure biological function protein, diagnosis drug order promote researchers’ further understanding lay theoretical foundation for possible outbreak sudden diseases future.

Language: Английский

Citations

7
SARS‐CoV‐2 nucleocapsid: Biological functions and implication for disease diagnosis and vaccine design DOI

Faezeh Maghsood,

Ahmad Ghorbani, Hamidreza Yadegari

et al.

Reviews in Medical Virology, Journal Year: 2023, Volume and Issue: 33(3)

Published: Feb. 15, 2023

The coronavirus disease 2019 (COVID-19) pandemic is transmitted by severe acute respiratory syndrome 2 (SARS-CoV-2) and has affected millions of people all around the world, leading to more than 6.5 million deaths. nucleocapsid (N) phosphoprotein plays important roles in modulating viral replication transcription, virus-infected cell cycle progression, apoptosis, regulation host innate immunity. As an immunodominant protein, N protein induces strong humoral cellular immune responses COVID-19 patients, making it a key marker for studying N-specific B T development diagnostic serological assays efficient vaccines. In this review, we focus on structural functional features kinetic epitope mapping against SARS-CoV-2 extend our understanding sensitive specific immunological tests effective

Language: Английский

Citations

15
The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein DOI Creative Commons
Noe Juvenal Mendoza-Ramírez, Julio García‐Cordero, Gaurav Shrivastava

et al.

Journal of Immunology Research, Journal Year: 2024, Volume and Issue: 2024, P. 1 - 18

Published: May 29, 2024

Vaccination is one of the most effective prophylactic public health interventions for prevention infectious diseases such as coronavirus disease (COVID-19). Considering ongoing need new COVID-19 vaccines, it crucial to modify our approach and incorporate more conserved regions severe acute respiratory syndrome 2 (SARS-CoV-2) effectively address emerging viral variants. The nucleocapsid protein a structural SARS-CoV-2 that involved in replication immune responses. Furthermore, this offers significant advantages owing minimal accumulation mutations over time inclusion key T-cell epitopes critical immunity. A novel strategy may be suitable generation vaccines against use combination antigens, including spike proteins, elicit robust humoral potent cellular responses, along with long-lasting strategic multiple antigens aims enhance vaccine efficacy broaden protection viruses, their response from other long-lasting, can persist up 11 years post-infection. Thus, incorporation nucleocapsids (N) into design adds an important dimension vaccination efforts holds promise bolstering ability combat effectively. In review, we summarize preclinical studies evaluated antigen. This study discusses alone its or proteins SARS-CoV-2.

Language: Английский

Citations

6
Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern DOI Creative Commons

Patrick O. Azevedo,

Natália Satchiko Hojo-Souza, Lídia Faustino

et al.

npj Vaccines, Journal Year: 2023, Volume and Issue: 8(1)

Published: Feb. 13, 2023

The current COVID-19 vaccines protect against severe disease, but are not effective in controlling replication of the Variants Concern (VOCs). Here, we used existing pre-clinical models and moderate to evaluate efficacy a Spike-based DNA vaccine (pCTV-WS) for protection different VOCs. Immunization transgenic (K18-hACE2) mice hamsters induced significant levels neutralizing antibodies (nAbs) Wuhan Delta isolates, Gamma Omicron variants. Nevertheless, pCTV-WS offered all Consistently, lung pathology viral load or was mediated by nAbs, whereas absence T cells controlled replication, disease lethality infected with either Hence, considering conserved nature CD4 CD8 cell epitopes, corroborate hypothesis that induction effector T-cells should be main goal new emergent SARS-CoV-2

Language: Английский

Citations

12
pGM-CSF as an adjuvant in DNA vaccination against SARS-CoV-2 DOI
Chang Liu,

Ruo‐Yi Xue,

Guocheng Li

et al.

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 264, P. 130660 - 130660

Published: March 7, 2024

Language: Английский

Citations

4
Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O) DOI Creative Commons
Pia Gattinger, Liubov I. Kozlovskaya,

Alexander S. Lunin

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 28, 2025

In this article we discuss characteristics of fusion protein-based SARS-CoV-2 vaccines. We focus on recombinant vaccine antigens comprising proteins consisting combinations SARS-CoV-2-derived or peptides antigens/peptides with SARS-CoV-2-unrelated proteins/peptides. These are made to increase the immunogenicity and/or enable special targeting immune system. The approach is exemplified solely in a proof concept study by using W-PreS-O, chimeric based single protein (W-PreS-O), combining RBDs from Wuhan hu-1 wild-type and Omicron BA.1 hepatitis B virus (HBV)-derived PreS surface antigen adsorbed aluminum hydroxide. W-PreS-O was evaluated Syrian hamsters which were immunized three times at three-week intervals hydroxide (placebo) before they infected BA.1. Neutralizing antibody (nAB) titers, weight, lung symptoms, viral loads, as measured RT-PCR upper lower respiratory tracts, determined. addition, infectious titers lungs plaque-forming assay. found that W-PreS-O-vaccinated developed robust nABs against BA.1, showed almost no development pneumonia, had significantly reduced lungs. Importantly, loads nasal cavities close above PCR cycle threshold considered be non-infectious. data our proof-of-concept provides compelling evidence has protective effect hamster vivo infection model thus support promising results obtained also for other

Language: Английский

Citations

0
Antiviral effect of Bromelain combined with acetylcysteine against SARS-CoV-2 Omicron variant DOI Creative Commons
Erik Vinicius de Sousa Reis,

Linziane Lopes Ferreira,

Felipe Alves Clarindo

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 7, 2025

The recent pandemic represented one of the biggest challenges modern civilization. SARS-CoV-2 remains an imminent public health threat and currently, there is no effective greatly affordable treatment for severe COVID-19. Although standard management with dexamethasone, physical including physiotherapy, prone positioning mechanical ventilation are used, disease patients may still succumb to infection. In this regard, BromAc® a combination therapy refined protein derived from Bromelain acetylcysteine, that shows significant mucolytic anti-inflammatory properties. present study, we performed in vitro, ex vivo analyses assess effect inhibiting Omicron variant at different levels. Here, provide evidence vitro virucidal activity Vero-ACE2/TMPRSS2 cell line infected variant. can also abrogate RNA genomic copies tracheal aspirate (TA) samples critically ill COVID-19 after long term exposure. These results were confirmed by lower spike expression observed EpCAM+PanCKneg epithelial cells treatment. Furthermore, atomized promoted cleavage S1 Spike subunit TA samples, demonstrating mechanism antiviral displayed human samples. bring novel lines as well patients, which support its potential use adjunct future waves subvariants.

Language: Английский

Citations

0